Royalty Pharma PLC
Royalty Pharma's GHG Emissions Data Preview
In 2023, Royalty Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 3 (indirect emissions across the value chain).
Royalty Pharma has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Royalty Pharma's Operational Emissions
No operational GHG emissions data disclosed for $Royalty Pharma in $2023.
Insights into Royalty Pharma's Value Chain Emissions
In 2023, Royalty Pharma reported 32,002 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Royalty Pharma includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Royalty Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Royalty Pharma's Scope 3 emissions?
In 2023, Royalty Pharma reported total Scope 3 emissions of 32,002 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 0% of these emissions originated from upstream activities such as purchased goods and capital goods, while 100% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Royalty Pharma reduced its Scope 3 emissions over time?
Since 2021, Royalty Pharma's Scope 3 emissions have increased by 73.5%, reflecting a rising long-term trend in Scope 3 emissions over time.
Compared to the previous year (2022), Royalty Pharma's Scope 3 emissions increased by 63.19%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Royalty Pharma disclose?
In 2023, Royalty Pharma reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Royalty Pharma's Scope 3 emissions?
In 2023, the largest contributors to Royalty Pharma's Scope 3 emissions were:
- Investments (Cat. 15): 32,002 tCOâ‚‚e (100%)